РИТУКСИМАБ: НОВЫЕ ВОЗМОЖНОСТИ ЛЕЧЕНИЯ ТЯЖЕЛОГО РЕФРАКТЕРНОГО ЮВЕНИЛЬНОГО АРТРИТА
Аннотация
Ключевые слова: дети, лечение, ритуксимаб, В-клетки, ювенильный артрит.
(Вопросы современной педиатрии. – 2008; 7(2):22-29)
Об авторах
Е.И. АлексееваРоссия
Т.М. Бзарова
Россия
С.И. Валиева
Россия
К.Б. Исаева
Россия
А.М. Чомахидзе
Россия
Е.Л. Семикина
Россия
Список литературы
1. Firestein G.S. Evolving concepts of rheumatoid arthritis. Nature. 2003; 423: 356–361.
2. Panayi G.S. The immunopathogenesis of rheumatoid arthritis. Br. J. Rheumatol. 1993; 32 (Suppl. 1): 4–14.
3. Edwards J.C., Cambridge G., Abrahams V.M. Do self perpetuating B lymphocytes drive human autoimmune disease? Immunology. 1999; 97: 188–196.
4. Edwards J.C., Szczepanski L., Szechinski J. Efficacy of B-Cell Targeted Therapy with Rituximab in Patients with Rheumatoid Arthritis. N. Engl. J. Med. 2004; 350: 2572–2581.
5. Leandro M.J., Edwards J.C., Cambridge G. Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann. Rheum. Dis. 2002; 61: 883–888.
6. Leandro M.J., Edwards J.C., Cambridge G. et al. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum. 2002; 46: 2673–2677.
7. Oligino T.J., Dalrymple S.A. Targeting B cells for the treatment of rheumatoid arthritis. Arthritis Res. Ther. 2003; 5 (Suppl. 4): 7–11.
8. Gause A., Berek C. The role of B cells in the pathogenesis of rheumatoid arthritis: potential implications for treatment. Bio Drugs. 2001; 15: 73–79.
9. Zhang Z., Bridges S.L. Jr. Pathogenesis of rheumatoid arthritis: role of B lymphocytes. Rheum. Dis. Clin. North. Am. 2001; 27: 335–353.
10. Daming Shan, Jeffrey A. Ledbetter, and Oliver W. Press Apoptosis of Malignant Human B Cells by Ligation of CD20 with Monoclonal Antibodies. Blood. 2006; 91: 1644–1652.
11. McLaughlin P., GrilloBLopez A.J., Link B.K. et al. Rituximab chimeric antiBCD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four dose treatment program. J. Clin. Oncol. 1998; 16: 2825–2833.
12. Panayi G.S. B cellBdirected therapy in rheumatoid arthritis — clinical experience. J. Rheumatol. Suppl. 2005; 73: 19–24.
13. Plosker G.L., Figgitt D.P. Rituximab: a review of its use in non-Hodgkin’s lymphoma and chronic lymphocytic leukaemia. Drugs. 2003; 63: 803–843.
14. Hainsworth John D. Safety of rituximab in the treatment of B cell malignancies: implications for rheumatoid arthritis. Arthritis Res. Ther. 2003; 5 (Suppl. 4): 12–16.
15. Anolik J.H., Campbell D., Felgar R.E. et al. The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum. 2003; 48: 455–459.
16. Bhat N.M., Lee L.M., van Vollenhoven R.F. et al. VH4B34 encoded antibody in systemic lupus erythematosus: effect of isotype. J. Rheumatol. 2002; 29: 2114–2121.
17. Pugh-Bernard A.E., Silverman G.J., Cappione A.J. et al. Regulation of inherently autoreactive VH4B34 B cells in the maintenance of human B cell tolerance. J. Clin. Invest. 2001; 108: 1061–1070.
18. Leandro M.J., Ehrenstein M.R., Edwards J.C., et al. Treatment of refractory lupus nephritis with B lymphocyte depletion. Arthritis. Rheum. 2003; 48: 378.
19. Patel K., Berman J., Ferber A. et al. Refractory autoimmune thrombocytopenic purpura treatment with rituximab. Am. J. Hematol. 2001; 67: 59–60.
20. Stasi R., Pagano A., Stipa E. et al. Rituximab chimeric antiCD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood. 2001; 98: 952–957.
21. Berentsen S., Tjonnfjord G.E., Brudevold R. et al. Favourable response to therapy with the antiBCD20 monoclonal antibody rituximab in primary chronic cold agglutinin disease. Br. J. Haematol. 2001; 115: 79–83.
22. Quartier P., Brethon B., Philippet P. et al. Treatment of childhood autoimmune haemolytic anaemia with rituximab. Lancet. 2001; 358: 1511–1513.
23. Zecca M., Nobili B., Ramenghi U. et al. Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood. 2003; 101: 3857–3861.
24. Ruggenenti P., Chiurchiu C., Brusegan V. et al. Rituximab in idiopathic membranous nephropathy: a oneByear prospective study. J. Am. Soc. Nephrol. 2003; 14: 1851–1857.
25. Levine T.D. Rituximab in the treatment of dermatomyositis: an open label pilot study. Arthritis Rheum. 2005; 52 (2): 601–607.
26. Xiao X., Heeringa P., Hu P. et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J. Clin. Invest. 2002; 110: 955–963.
27. Eriksson P. Short term outcome and safety in 5 patients with ANCABpositive vasculitis treated with rituximab: 11th International Vasculitis and ANCA Workshop 2003. Kidney Blood Pressure Res. 2003; 26: 294.
28. Jayne D., Burns S., Smith K. A prospective, open label trial of B cell depletion with rituximab in refractory systemic vasculitis. 11th International Vasculitis and ANCA Workshop 2003. Kidney Blood Pressure Res. 2003; 26: 294.
29. Edwards J.C., Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete lymphocytes. Rheumatology. 2001; 40: 205–211.
30. Looney R.J., Anolik J., Sanz I. B cells as therapeutic targets for rheumatic diseases. Current Opinion Rheumatology. 2004; 16: 180–185.
31. Stahl H.D., Szczepanski L., Szechinski J. et al. Rituximab in RA: efficacy and safety from a randomized controlled trial. Ann. Rheum. Dis. 2003; 62: 65.
32. Emery P., Szczepanski L., Szechinski J. et al. Sustained efficacy at 48 weeks after a single treatment course of rituximab in patients with RA. Arthritis Rheum. 2003; 48: 439.
Рецензия
Для цитирования:
Алексеева Е., Бзарова Т., Валиева С., Исаева К., Чомахидзе А., Семикина Е. РИТУКСИМАБ: НОВЫЕ ВОЗМОЖНОСТИ ЛЕЧЕНИЯ ТЯЖЕЛОГО РЕФРАКТЕРНОГО ЮВЕНИЛЬНОГО АРТРИТА. Вопросы современной педиатрии. 2008;7(2):22-29.
For citation:
Alexeeva E., Bzarova T., Valieva S., Isaeva K., Chomakhidze A., Semikina E. RITUXIMAB: NEW RESOURCES OF MANAGEMENT OF SEVERE REFRACTORY JUVENILE RHEUMATOID ARTHRITIS. Current Pediatrics. 2008;7(2):22-29.
Послать статью по эл. почте 
